24 completed, 6 terminated, 3 withdrawn, 1 recruiting. 34 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 34 | Completed 24, Terminated 6, Withdrawn 3, Recruiting 1 |
| Phase 2 | 8 | Completed 5, Withdrawn 2, Terminated 1 |
Follow CSL Behring: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD) CSL300, Placebo - End Stage Kidney Disease (ESKD) | Phase 1 | Recruiting | CSL Behring | 24 | 2026-06-17 | 2026-07-07 |
| Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults Vamifeport (PR formulation) - Healthy Volunteers | Phase 1 | Completed | CSL Behring | 28 | 2025-05-27 | 2025-11-21 |
| Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults Vamifeport IRF, Vamifeport PR1, Vamifeport PR2 - Healthy Volunteers | Phase 1 | Completed | CSL Behring | 22 | 2024-11-22 | 2025-06-27 |
| First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects CSL040, Placebo - Complement-mediated Disorders | Phase 1 | Completed | CSL Behring | 62 | 2023-09-28 | 2026-02-03 |
| Effects of CSL324 in the Lung After Segmental Challenge CSL324, Placebo - Healthy Volunteers | Phase 1 | Completed | CSL Behring | 40 | 2022-12-20 | 2023-11-29 |
| A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects CSL312 - Healthy Participants | Phase 1 | Completed | CSL Behring | 132 | 2022-04-04 | 2022-10-06 |
| Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease CSL889 - Sickle Cell Disease | Phase 1 | Completed | CSL Behring | 28 | 2021-05-20 | 2023-09-06 |
| Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects CSL760 - Coronavirus Disease 2019 (COVID-19) | Phase 1 | Terminated | CSL Behring | 12 | 2021-02-02 | 2021-12-10 |
| A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH) fibrinogen concentrate, Placebo - Postpartum Hemorrhage | Phase 1 / Phase 2 | Withdrawn | Yale University | 2021-01-01 | 2021-03-15 | |
| Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) CSL787, Placebo - Noncystic Fibrosis Bronchiectasis (NCFB) | Phase 1 | Completed | CSL Behring | 64 | 2020-12-07 | 2023-12-15 |
| A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults CSL312 - Healthy Volunteers | Phase 1 | Completed | CSL Behring | 38 | 2020-10-29 | 2022-10-04 |
| Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects CSL324, Placebo - Healthy | Phase 1 | Completed | CSL Behring | 32 | 2020-10-08 | 2022-10-04 |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects CSL730, Placebo - Immune Complex-mediated Autoimmune Diseases | Phase 1 | Terminated | CSL Behring | 52 | 2020-09-23 | 2023-11-29 |
| A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line CSL312, Placebo - PICC-associated Thrombosis | Phase 1 / Phase 2 | Withdrawn | CSL Behring | 2020-03-01 | 2020-03-25 | |
| A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers Human beta common receptor antagonist monoclonal antibody, Placebo - Asthma | Phase 1 | Completed | CSL Behring | 78 | 2019-11-28 | 2024-01-10 |
| CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 - Anemia, Sickle Cell | Phase 1 | Terminated | CSL Behring | 1 | 2019-10-02 | 2021-06-18 |
| Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody - Hidradenitis Suppurativa, Palmoplantar Pustulosis | Phase 1 | Completed | CSL Behring | 39 | 2019-07-04 | 2023-05-26 |
| Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency Salmonella typhi polysaccharide vaccine - Immune Deficiency | Phase 1 | Completed | University of Virginia | 37 | 2019-07-01 | 2024-03-29 |
| A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma Cal-1 (LVsh5/C46) drug product - HIV-1 Infection | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 2 | 2019-01-15 | 2025-11-20 |
| Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults CSL730, Placebo - Healthy | Phase 1 | Terminated | CSL Behring | 26 | 2018-01-10 | 2021-06-03 |
Showing 20 of 34. Sign in to see all of them.
Hemophilia B (4) · Anemia, Sickle Cell (2) · Hereditary Angioedema Types I and II (2) · Thrombosis (2) · Asthma (1) · Atherosclerosis (1) · COVID-19 (1) · Cystic Fibrosis (1) · Diabetes Mellitus (1) · Hidradenitis Suppurativa (1) · Immunologic Deficiency Syndromes (1) · Iron Overload (1) · Ischemic Stroke (1) · Kidney Failure, Chronic (1) · Lymphoma (1)
Complement C1 Inhibitor Protein (2) · Granulocyte Colony-Stimulating Factor (2) · Saline Solution (2) · Sodium Chloride (2) · CSL112 (1) · Dosage Forms (1) · Fibrinogen (1) · Fluid Therapy (1) · Hizentra (1) · Immunoglobulins, Intravenous (1) · Vi polysaccharide vaccine, typhoid (1) · albutrepenonacog alfa (1) · apixaban (1) · clazakizumab (1) · gamma-Globulins (1)
United States (11) · Germany (10) · United Kingdom (9) · Australia (4) · Netherlands (4) · Bulgaria (2) · Denmark (2) · France (2) · Israel (2) · Austria (1) · China (1) · Hungary (1) · Italy (1) · Norway (1) · Poland (1)
Iris Jacobs, MD (2) · Alex Veldman (1) · Alex Veldman, M.D. (1) · Beverly C Walters, MD (1) · Denise D'Andrea, M.D. (1) · Ghazala Hayat, M.D. (1) · Jack Cochran, MD (1) · Jafar Kafaie, M.D. (1) · Javier San Martin, MD FRCP (1) · Larry Borish, MD (1) · Michael J Paidas, MD (1)
PMID 40386832, PMID 22859609, PMID 24112951, PMID 25606785, PMID 26016741, PMID 27170068, PMID 29246900, PMID 30240132, PMID 33217027
2019 (3), 2014 (2), 2015 (1), 2017 (1), 2018 (1)